| Company Name: |
Bide Pharmatech Ltd.
|
| Tel: |
400-1647117 13681763483 |
| Email: |
product02@bidepharm.com |
| Products Intro: |
Product Name:5-Acryloyl-2-(4-fluorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one
CAS:1448990-73-5
Purity:98% Package:25mg;50mg;100mg; Remarks:BD01479436
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:GSK-3β inhibitor 3
CAS:1448990-73-5
Purity:97.53% Package:1mg/RMB 892;5mg/RMB 1980;10mg/RMB 2970
|
1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)- manufacturers
- GSK-3β inhibitor 3
-
- $84.00 / 1mg
-
2024-11-19
- CAS:1448990-73-5
- Min. Order:
- Purity: 97.53%
- Supply Ability: 10g
|
| | 1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)- Basic information |
| Product Name: | 1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)- | | Synonyms: | 1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)-;GSK-3β inhibitor 3;GSK3β inhibitor 3,GSK 3β inhibitor 3;5-Acryloyl-2-(4-fluorophenyl)-2,3-dihydrobenzo[b][1,4]thiazepin-4(5H)-one;GSK-3β inhibitor 3, 10 mM in DMSO | | CAS: | 1448990-73-5 | | MF: | C18H14FNO2S | | MW: | 327.37 | | EINECS: | | | Product Categories: | | | Mol File: | 1448990-73-5.mol |  |
| | 1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)- Chemical Properties |
| Boiling point | 489.0±45.0 °C(Predicted) | | density | 1.297±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 250 mg/mL (763.66 mM; Need ultrasonic) | | form | Solid | | pka | -0.61±0.40(Predicted) | | color | White to off-white |
| | 1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)- Usage And Synthesis |
| Biological Activity | GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC50 of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia[1].
GSK-3β inhibitor 3 (compound 4-3) (100 μM) inhibits GSK-3α activity by 87.3%[1].GSK-3β inhibitor 3 (6.25-100 μM; 24-48 h) dose-dependently inhibits the growth of NB4 and NB4-R1 cells[1].GSK-3β inhibitor 3 (12.5-100 μM; 24 h) significantly increases the percentage of apoptosis in a dose-dependent pattern in NB4 and NB4-R1 cells[1].
GSK-3β inhibitor 3 (compound 4-3) (15 mg/kg/d; i.p. for 2 weeks) inhibits tumor growth of mice by 75.97% relative to vehicle control[1].GSK-3β inhibitor 3 (15 mg/kg; a single i.p.) shows long T1/2 of 14.2 h, high AUC values (AUClast=3503.42 ng/mL?h), and maximum concentration (Cmax=515 ng/mL) in mice[1]. | | References | [1]. Zhang P, et, al. Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia. J Med Chem. 2021 May 24. |
| | 1,5-Benzothiazepin-4(5H)-one, 2-(4-fluorophenyl)-2,3-dihydro-5-(1-oxo-2-propen-1-yl)- Preparation Products And Raw materials |
|